Zymeworks stock hits four-year high on promising results from digestive cancer trial

theglobeandmail.com/business/article-zymeworks-stock-four-year-high-digestive-cancer-trial-ziihera

Zymeworks Inc. ZYME-Q stock hit its highest level in four years Monday, on news that the clinical-stage biotechnology company’s lead drug had proven effective in controlling the spread of a digestive system cancer.
The Vancouver-based company’s drug Ziihera, when combined with…

This story appeared on theglobeandmail.com, 2025-11-18 01:43:13.
The Entire Business World on a Single Page. Free to Use →